1. Home
  2. SIGA vs TNXP Comparison

SIGA vs TNXP Comparison

Compare SIGA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SIGA Technologies Inc.

SIGA

SIGA Technologies Inc.

HOLD

Current Price

$3.15

Market Cap

223.8M

Sector

Health Care

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$5.68

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIGA
TNXP
Founded
1995
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.8M
199.7M
IPO Year
2016
2008

Fundamental Metrics

Financial Performance
Metric
SIGA
TNXP
Price
$3.15
$5.68
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $44.50
AVG Volume (30 Days)
590.9K
★ 889.4K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 18.93%
N/A
EPS Growth
N/A
★ 91.75
EPS
★ 0.13
N/A
Revenue
N/A
★ $13,107,000.00
Revenue This Year
N/A
$319.65
Revenue Next Year
$170.70
$101.60
P/E Ratio
$24.38
★ N/A
Revenue Growth
N/A
★ 29.85
52 Week Low
$2.83
$6.01
52 Week High
$8.54
$20.58

Technical Indicators

Market Signals
Indicator
SIGA
TNXP
Relative Strength Index (RSI) 45.66 14.28
Support Level $2.87 N/A
Resistance Level $3.32 $12.99
Average True Range (ATR) 0.14 0.55
MACD -0.02 -0.15
Stochastic Oscillator 17.97 0.59

Price Performance

Historical Comparison
SIGA
TNXP

About SIGA SIGA Technologies Inc.

SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: